RESUMO
BACKGROUND: The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer's disease (AD). METHODS: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test "normal" on a battery of cognitive tests and to be age 70+ with a family history of Alzheimer-like dementia. Persons were randomly assigned to 200 mg b.i.d. celecoxib (Celebrex, Pfizer), 220 mg b.i.d. naproxen sodium (Aleve, Bayer), or placebo. The primary outcome measure was AD. Secondary outcome measures were cognitive decline and measures related to safety of the treatments when used long term. ADAPT was designed to detect a 30% reduction in AD incidence with 80% power. The estimated sample size requirement was 2,625. RESULTS: Enrollment began in March 2001 and ended in December 2004 when treatments were suspended because of concerns regarding cardiovascular safety of the treatments. Followup ranged from 1 to 46 months. The achieved enrollment was 2,528. Recruitment was achieved primarily via mailings to people aged 70+ living in the catchment areas of the six field sites.
Assuntos
Doença de Alzheimer/prevenção & controle , Anti-Inflamatórios não Esteroides/administração & dosagem , Encéfalo/efeitos dos fármacos , Encefalite/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/fisiopatologia , Anti-Inflamatórios não Esteroides/efeitos adversos , Encéfalo/metabolismo , Encéfalo/fisiopatologia , Celecoxib , Transtornos Cognitivos/tratamento farmacológico , Transtornos Cognitivos/fisiopatologia , Transtornos Cognitivos/prevenção & controle , Encefalite/tratamento farmacológico , Encefalite/fisiopatologia , Feminino , Humanos , Masculino , Naproxeno/administração & dosagem , Testes Neuropsicológicos , Avaliação de Resultados em Cuidados de Saúde/métodos , Seleção de Pacientes , Placebos , Pirazóis/administração & dosagem , Projetos de Pesquisa , Sulfonamidas/administração & dosagem , Tempo , Resultado do TratamentoRESUMO
Racial disparities in asthma morbidity and mortality are greater than differences in asthma prevalence. This finding suggests that following the diagnosis of asthma, blacks receive substantially different care than non-Hispanic whites, through available health care systems and their social support networks, and racial differences in relevant environ-mental exposures contribute to differences in morbidity and mortality. An overview of factors that may contribute to disparities in asthma prevalence, morbidity, and mortality,including contextual factors, is provided.
Assuntos
Asma/epidemiologia , Negro ou Afro-Americano , Poluentes Atmosféricos , Alérgenos , Asma/genética , Asma/mortalidade , Asma/terapia , Exposição Ambiental , Humanos , Apoio Social , Fatores Socioeconômicos , Estresse Psicológico , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: The National Eye Institute Visual Function Questionnaire (NEI-VFQ) measures vision-targeted quality of life, but it is unclear whether it is sensitive to changes within individuals over time. OBJECTIVE: To determine the responsiveness of the NEI-VFQ to "within-individual" changes in visual acuity in patients who had subfoveal choroidal neovascularization in at least one eye secondary to age-related macular degeneration, ocular histoplasmosis syndrome, or idiopathic causes, and who participated in randomized trials of submacular surgery. METHODS: Trained telephone interviewers administered the NEI-VFQ as part of annual follow-up data collection for pilot trials and larger clinical trials of submacular surgery. Best-corrected visual acuity was measured by local vision examiners at 12 months after enrollment and, typically, by central "traveling" vision examiners at 24 months after enrollment. Changes in visual acuity and NEI-VFQ scores from 12 to 24 months were analyzed using linear regression methods. RESULTS: Two-hundred eighteen patients had both interviews and visual acuity measurements at 12 and 24 months after enrollment. Changes in the overall NEI-VFQ score and in 9 of the subscales (near activities, dependency, driving, role difficulties, distance activities, mental health, general vision, peripheral vision, and social functioning) were related to changes in visual acuity of the better-seeing eye based on linear regression analysis (P<.05). In our analysis, a 3-line decrease in the visual acuity of the better-seeing eye was associated with 3.6- to 16.2-point decreases in the overall NEI-VFQ score and 9 subscale scores. CONCLUSIONS: Most of the NEI-VFQ subscales were responsive to changes in the visual acuity of the better-seeing eye over a 12-month interval in this patient population. Thus, the NEI-VFQ can be used to measure change in vision-targeted quality of life over time to augment clinical measurements of visual acuity.
Assuntos
Neovascularização de Coroide/fisiopatologia , Fóvea Central/fisiopatologia , National Institutes of Health (U.S.)/normas , Inquéritos e Questionários , Acuidade Visual/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Neovascularização de Coroide/etiologia , Infecções Oculares Fúngicas/complicações , Infecções Oculares Fúngicas/fisiopatologia , Feminino , Nível de Saúde , Indicadores Básicos de Saúde , Histoplasmose/complicações , Histoplasmose/fisiopatologia , Humanos , Degeneração Macular/complicações , Degeneração Macular/fisiopatologia , Masculino , Pessoa de Meia-Idade , Oftalmologia , Qualidade de Vida , Estados UnidosRESUMO
PURPOSE: To describe the effect of subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD) on health-related quality of life (HRQOL) of patients at enrollment in two randomized clinical trials; to examine the relation of visual acuity to HRQOL; to compare HRQOL scores between participants with unilateral and bilateral CNV independent of other characteristics. DESIGN: Randomized clinical trials. METHODS: Two Submacular Surgery Trials (SST) recruited patients with AMD and either new subfoveal CNV (Group N Trial) or predominantly hemorrhagic CNV (Group B Trial). Health-related quality of life interviews included the National Eye Institute Visual Function Questionnaire [NEI-VFQ], the SF-36 Health Survey, and the Hospital Anxiety and Depression Scale [HADS]. Linear correlation and regression analyses were used to relate baseline HRQOL scores to visual acuity and bilateral disease. RESULTS: Interview data were analyzed for 789 AMD patients: 454 patients in the Group N Trial and 335 patients in the Group B Trial. Participants reported poor vision-related functioning in many domains measured by the NEI-VFQ (mean overall scores of 65 for Group N and 63 for Group B). Visual acuity of the better eye was strongly associated with NEI-VFQ scores but not with SF-36 or HADS scores. After adjusting for visual acuity of the better eye and other factors, bilateral cases had NEI-VFQ overall scores six points lower than unilateral cases in Group N Trial and 10 points lower than unilateral cases in the Group B Trial. CONCLUSIONS: Subfoveal CNV profoundly affects vision-related quality of life. The effect is more pronounced with bilateral disease, even after controlling for visual acuity.
Assuntos
Neovascularização de Coroide/psicologia , Nível de Saúde , Degeneração Macular/psicologia , Qualidade de Vida/psicologia , Acuidade Visual/fisiologia , Idoso , Idoso de 80 Anos ou mais , Neovascularização de Coroide/etiologia , Feminino , Angiofluoresceinografia , Humanos , Degeneração Macular/complicações , Masculino , Pessoa de Meia-Idade , National Institutes of Health (U.S.) , Perfil de Impacto da Doença , Inquéritos e Questionários , Estados UnidosRESUMO
BACKGROUND: Many risk factors have been associated with cancer, such as age, family history, race, smoking, high-fat diet, and poor nutrition. It is important to reveal the molecular changes related to risk factors that could facilitate early detection, prevention, and overall control of cancer. METHODS: We selected six cancer-specific methylated genes that have previously been reported in primary tumors and have also been detected in different bodily fluids of cancer patients. Here, we used quantitative fluorogenic real-time methylation-specific PCR in plasma DNA samples for the detection of methylation changes from an asymptomatic population who do not have any known cancer. RESULTS: The promoter methylation frequencies of the studied genes were as follows: APC (7%), CCND2 (22%), GSTP1 (2%), MGMT (9%), RARbeta2 (29%), and P16 (3%). Promoter methylation of at least one of the genes analyzed was observed in approximately 46% (72 of 157) of the samples by binary dichotomization. Promoter hypermethylation of at least two genes was detected in 17% (26 of 157) of the samples. RARbeta2 methylation was observed in 45% of subjects who had a high-fat diet in contrast with those who had a low-fat diet (23%; P = 0.007). DISCUSSION: Our findings may help to elucidate early methylation changes that may lead to cancer development. These methylation changes could be due to exposure to risk factors and may be useful for cancer prevention measures such as changes in lifestyle. Longitudinal follow-up of a high-risk population is needed to understand the association of methylation of candidate genes in cancer development.